Journal of Renal Nutrition
Volume 18, Issue 3 , Pages 256-261 , May 2008

Public Health Approach to Addressing Hyperphosphatemia Among Dialysis Patients

  • Ashwini R. Sehgal, MD

      Affiliations

    • Division of Nephrology, MetroHealth Medical Center, Cleveland, OH
    • Department of Public Health, City of Cleveland, Cleveland, OH
    • Center for Reducing Health Disparities, Case Western Reserve University, Cleveland, OH
    • Center for Health Care Research and Policy, MetroHealth Medical Center, Cleveland, OH
    • Department of Medicine, Case Western Reserve University, Cleveland, OH
    • Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
    • Department of Bioethics, Case Western Reserve University, Cleveland, OH
    • Corresponding Author InformationAddress reprint requests to Ashwini R. Sehgal, MD, Division of Nephrology, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109.
    • ,
  • Catherine Sullivan, MS

      Affiliations

    • Division of Nephrology, MetroHealth Medical Center, Cleveland, OH
    • Center for Reducing Health Disparities, Case Western Reserve University, Cleveland, OH
    • ,
  • Janeen B. Leon, MS, RD, LD

      Affiliations

    • Division of Nephrology, MetroHealth Medical Center, Cleveland, OH
    • Center for Reducing Health Disparities, Case Western Reserve University, Cleveland, OH
    • ,
  • Karil Bialostosky, MS

      Affiliations

    • Department of Public Health, City of Cleveland, Cleveland, OH

References 

  1. NKF-K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Accessed September 29, 2006. Available at http://www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_nut.html
  2. NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Accessed September 29, 2006. Available at http://www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm
  3. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  4. Al Aly Z, Gonzalez EA, Martin KJ, et al. Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle. Am J Nephrol. 2004;24:422–426
  5. Kimata N, Akiba T, Pisoni RL, et al. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2005;20:927–935
  6. Lorenzo V, Martin-Malo A, Perez-Garcia R, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: A cross-sectional multicentre study. Nephrol Dial Transplant. 2006;21:459–465
  7. Elder JP, Talavera GA, Gorbach PM, et al. Theories and structures of public health behavior. In:  Scutchfield FD,  Keck CW editor. Principles of Public Health Practice. Clifton Park, NY: Delmar Learning; 2003;p. 253–272
  8. Mitch WE, Klahr S. Handbook of Nutrition and the Kidney. Philadelphia: Lippincott-Raven; 1998;
  9. Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol. 2000;54:318–324
  10. Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens. 2001;10:563–568
  11. Cozzolino M, Brancaccio D, Gallieni M, et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 2005;68:429–436
  12. London G. Cardiovascular calcifications in uremic patients. J Am Soc Nephrol. 2003;14(suppl):S305–S309
  13. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  14. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–2138
  15. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46:68–77
  16. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37(suppl):S54–S57
  17. Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33:287–293
  18. Stein MS, Packham DK, Ebeling PR, et al. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis. 1996;28:515–522
  19. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: Does it matter in nephrology?. Semin Dial. 2003;16:186–188
  20. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure. Kidney Int. 2002;62:367–374
  21. Bellasi A, Kooienga L, Block GA. Phosphate binders: New products and challenges. Hemodial Int. 2006;10:225–234
  22. Stamatakis M, Pecora P, Gunel E. Factors influencing adherence in chronic dialysis patients with hyperphosphatemia. J Ren Nutr. 1997;7:144–148
  23. Weed-Collins M, Hogan R. Knowledge and health beliefs regarding phosphate-binding medication in predicting compliance. ANNA J. 1989;16:278–282
  24. Barsotti G, Lazzeri M, Cristofano C, et al. The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab. 1986;12:103–106
  25. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  26. Drueke TB. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrol Dial Transplant. 2002;17(suppl 11):20–22
  27. Olson JA, Leight GS. Surgical management of secondary hyperparathyroidism. Adv Ren Replace Ther. 2002;9:209–218
  28. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33:694–701
  29. Cohen DA, Scribner RA, Farley TA. A structural model of health behavior: A pragmatic approach to explain and influence health behaviors at the population level. Prev Med. 2000;30:146–154
  30. Consumers Union: Out of Balance: Marketing of Soda, Candy, Snacks and Fast Foods Drowns out Healthful Messages. Accessed October 2, 2006. Available at http://www.consumersunion.org/pdf/OutofBalance.pdf
  31. United States Department of Agriculture: Nutrient Content of the U.S. Food Supply. Accessed October 2, 2006. Available at http://www.cnpp.usda.gov/USFoodSupply.htm
  32. Young LR, Nestle M. Expanding portion sizes in the US marketplace: Implications for nutrition counseling. J Am Diet Assoc. 2003;103:231–234
  33. Jetter KM, Cassady DL. The availability and cost of healthier food alternatives. Am J Prev Med. 2006;30:38–44
  34. Soinski J, Kelly K, Komaransky ZA. Determination of monthly food cost factor for a reference renal diet. J Ren Nutr. 1993;3:141–145
  35. Drewnowski A, Darmon N. The economics of obesity: Dietary energy density and energy cost. Am J Clin Nutr. 2005;82(suppl):265S–273S
  36. Loghman-Adham M. Medication noncompliance in patients with chronic disease: Issues in dialysis and renal transplantation. Am J Manag Care. 2003;9:155–171
  37. Block JP, Scribner RA, DeSalvo KB. Fast food, race/ethnicity, and income: A geographic analysis. Am J Prev Med. 2004;27:211–217
  38. Moore LV, Diez Roux AV. Associations of neighborhood characteristics with the location and type of food stores. Am J Public Health. 2006;96:325–331
  39. Nestle M. What to Eat. New York: North Point Press; 2006;
  40. Dwyer JT, Cunniff PJ, Maroni BJ, et al. The Hemodialysis Pilot Study: Nutrition program and participant characteristics at baseline. The HEMO Study Group. J Ren Nutr. 1998;8:11–20
  41. Kalantar-Zadeh K, Kopple JD, Deepak S, et al. Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr. 2002;12:17–31
  42. Bell RR, Draper HH, Tzeng DY, et al. Physiological responses of human adults to foods containing phosphate additives. J Nutr. 1977;107:42–50
  43. Murphy-Gutekunst L. Hidden phosphorus in popular beverages. J Ren Nutr. 2005;15:e1–e6
  44. Leon JB, Albert JM, Gilchrist G, et al. Improving albumin levels among hemodialysis patients: A community-based randomized controlled trial. Am J Kidney Dis. 2006;48:28–36
  45. Sehgal AR, Leon J, Soinski JA. Barriers to adequate protein nutrition among hemodialysis patients. J Ren Nutr. 1998;8:179–187
  46. Linn SE. Food marketing to children in the context of a marketing maelstrom. J Public Health Policy. 2004;25:367–378
  47. Mello MM, Studdert DM, Brennan TA. Obesity—The new frontier of public health law. N Engl J Med. 2006;354:2601–2610
  48. Wald N, Willett W. Reversing the obesity epidemic. Lancet. 2004;364:140
  49. Cawley J. Markets and childhood obesity policy. Future Child. 2006;16:69–88
  50. Center for Science in the Public Interest: Food Processors and Supermarkets Move Forward on Trans Fat. Accessed October 25, 2006. Available at http://www.cspinet.org/new/200511221.html
  51. US Renal Data System . USRDS 2005 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  52. NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Accessed September 29, 2006. Available at http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm
  53. Sax L. The Institute of Medicine's “dietary reference intake” for phosphorus: A critical perspective. J Am Coll Nutr. 2001;20:271–278

 Supported by grant DK51472 from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, and by the Leonard C. Rosenberg Renal Research Foundation, Cleveland, Ohio.

PII: S1051-2276(07)00303-2

doi: 10.1053/j.jrn.2007.12.002

Journal of Renal Nutrition
Volume 18, Issue 3 , Pages 256-261 , May 2008

Article Tools